Trial Profile
Safety and Immunogenicity Study of an Additional Dose of HPV Vaccine (580299) in Young, Adult Women in North America [EXTENSION OF 700015423]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 05 Feb 2013 New trial record